Skip to main content

NEA Management Company, LLC

13F filer · CIK 0001512848
Reported Aug 14, 2026
Net seller this quarter
13F portfolio value$1.59BU.S. long equity reported on 13F
Positions261 new · 1 closed
Net flow last quarter-$405MBuys minus sells
Top 10 positions weight89.8%Concentration

Holdings

13F · last 4 quarters free
Scroll for earlier quarters
CompanyValue% of portfolio% of companyPOSITION CHANGE qoq %First reported
Q2 2026Reported Aug 14, 202626 positions
TRVITrevi Therapeutics, Inc.$247M15.53%9.28%Not reportedQ2 2019
MBXMBX Biosciences, Inc.$200M12.56%7.54%Not reportedQ3 2024
GLUEMonte Rosa Therapeutics, Inc.$186M11.72%9.03%Not reportedQ2 2021
CELCCelcuity Inc.$179M11.27%3.50%-25.2%Q4 2022
SGPSpyGlass Pharma, Inc.$165M10.36%22.10%Not reportedQ1 2026
SVRASavara Inc$151M9.49%11.91%Not reportedQ1 2021
ZBIOZenas BioPharma, Inc.$102M6.43%6.35%Not reportedQ3 2024
COURCoursera, Inc.$72.6M4.57%4.69%Not reportedQ1 2021
AUPHAurinia Pharmaceuticals Inc.$67.4M4.24%2.99%Not reportedQ3 2014
CRSPCRISPR Therapeutics AG$57.7M3.64%1.10%Not reportedQ4 2016
ORICOric Pharmaceuticals, Inc.$44.6M2.81%3.97%Not reportedQ2 2024
PHATPhathom Pharmaceuticals, Inc.$21.3M1.34%2.45%Not reportedQ2 2023
KRROKorro Bio, Inc.$17.1M1.08%8.83%Not reportedQ4 2023
XFORX4 Pharmaceuticals, Inc$15.1M0.95%3.36%Not reportedQ1 2019
CSBRChampions Oncology, Inc.$10.6M0.66%12.34%Not reportedQ3 2015
NKTXNkarta, Inc.$10.1M0.64%4.99%Not reportedQ3 2020
CVRXCVRx, Inc.$10M0.63%7.34%-3.5%Q2 2021
BDTXBlack Diamond Therapeutics, Inc.$8.23M0.52%7.74%Not reportedQ1 2020
KPTIKaryopharm Therapeutics Inc.$5.64M0.35%2.54%NewQ2 2026
IVAInventiva S.A.$5.53M0.35%0.76%Not reportedQ3 2020
LONALeonaBio, Inc.$4.27M0.27%4.93%Not reportedQ4 2025
SNTISenti Biosciences Holdings, Inc.$4.15M0.26%12.12%Not reportedQ2 2022
MRKRMarker Therapeutics, Inc.$2.39M0.15%9.73%Not reportedQ4 2018
OKUROnKure Therapeutics, Inc.$2.18M0.14%1.18%Not reportedQ4 2024
IMAImageneBio, Inc.$295K0.02%0.44%Not reportedQ3 2025
GOSSGossamer Bio, Inc.$165K0.01%0.20%Not reportedQ3 2022
Q1 2026Reported May 15, 202626 positions
ACLXArcellx, Inc.$350M19.88%5.21%Not reportedQ1 2022
CELCCelcuity Inc.$261M14.83%4.73%-35.4%Q4 2022
SGPSpyGlass Pharma, Inc.$192M10.89%22.11%NewQ1 2026
TRVITrevi Therapeutics, Inc.$158M8.97%10.30%Not reportedQ2 2019
SVRASavara Inc$134M7.60%11.94%Not reportedQ1 2021
GLUEMonte Rosa Therapeutics, Inc.$127M7.19%9.12%Not reportedQ2 2021
MBXMBX Biosciences, Inc.$108M6.13%7.60%Not reportedQ3 2024
ZBIOZenas BioPharma, Inc.$78.7M4.47%6.45%+14.2%Q3 2024
COURCoursera, Inc.$74.9M4.26%7.60%Not reportedQ1 2021
AUPHAurinia Pharmaceuticals Inc.$58.8M3.34%3.04%Not reportedQ3 2014
ORICOric Pharmaceuticals, Inc.$52.2M2.97%3.98%Not reportedQ2 2024
CRSPCRISPR Therapeutics AG$50.4M2.86%1.10%Not reportedQ4 2016
PHATPhathom Pharmaceuticals, Inc.$21.8M1.24%2.47%Not reportedQ2 2023
CVRXCVRx, Inc.$19.2M1.09%7.67%Not reportedQ2 2021
KRROKorro Bio, Inc.$14.7M0.84%9.00%+19.0%Q4 2023
XFORX4 Pharmaceuticals, Inc$13.4M0.76%3.43%Not reportedQ1 2019
CSBRChampions Oncology, Inc.$9.85M0.56%12.34%Not reportedQ3 2015
BDTXBlack Diamond Therapeutics, Inc.$9.48M0.54%7.76%Not reportedQ1 2020
IVAInventiva S.A.$8.03M0.46%0.76%Not reportedQ3 2020
NKTXNkarta, Inc.$7.53M0.43%5.01%Not reportedQ3 2020
LONALeonaBio, Inc.$4.77M0.27%4.94%Not reportedQ4 2025
SNTISenti Biosciences Holdings, Inc.$3.07M0.17%12.12%Not reportedQ2 2022
MRKRMarker Therapeutics, Inc.$2.11M0.12%9.73%Not reportedQ4 2018
OKUROnKure Therapeutics, Inc.$1.98M0.11%3.50%Not reportedQ4 2024
GOSSGossamer Bio, Inc.$329K0.02%0.43%-94.5%Q3 2022
IMAImageneBio, Inc.$250K0.01%0.45%Not reportedQ3 2025
Q4 2025Reported Feb 17, 202627 positions
CELCCelcuity Inc.$353M17.98%7.33%+64.9%Q4 2022
RYTMRhythm Pharmaceuticals, Inc.$311M15.88%4.33%Not reportedQ4 2017
ACLXArcellx, Inc.$199M10.12%5.26%Not reportedQ1 2022
TRVITrevi Therapeutics, Inc.$166M8.44%10.31%Not reportedQ2 2019
SVRASavara Inc$148M7.52%11.96%Not reportedQ1 2021
ZBIOZenas BioPharma, Inc.$128M6.52%6.47%+28.9%Q3 2024
GLUEMonte Rosa Therapeutics, Inc.$121M6.15%11.74%Not reportedQ2 2021
MBXMBX Biosciences, Inc.$114M5.81%8.05%Not reportedQ3 2024
COURCoursera, Inc.$94.7M4.83%7.66%Not reportedQ1 2021
AUPHAurinia Pharmaceuticals Inc.$63.3M3.23%3.00%Not reportedQ3 2014
GOSSGossamer Bio, Inc.$56.1M2.86%7.74%Not reportedQ3 2022
CRSPCRISPR Therapeutics AG$55.5M2.83%1.10%Not reportedQ4 2016
ORICOric Pharmaceuticals, Inc.$33.7M1.72%4.18%Not reportedQ2 2024
PHATPhathom Pharmaceuticals, Inc.$32.5M1.66%2.74%Not reportedQ2 2023
CVRXCVRx, Inc.$14.4M0.73%7.70%Not reportedQ2 2021
XFORX4 Pharmaceuticals, Inc$12.9M0.66%3.56%+44.8%Q1 2019
CSBRChampions Oncology, Inc.$11.8M0.60%12.34%Not reportedQ3 2015
BDTXBlack Diamond Therapeutics, Inc.$10.8M0.55%7.79%Not reportedQ1 2020
KRROKorro Bio, Inc.$8.74M0.45%11.58%Not reportedQ4 2023
IVAInventiva S.A.$6.8M0.35%0.76%Not reportedQ3 2020
NKTXNkarta, Inc.$6.6M0.34%5.02%Not reportedQ3 2020
SNTISenti Biosciences Holdings, Inc.$3.93M0.20%12.23%Not reportedQ2 2022
LONALeonaBio, Inc.$3.52M0.18%4.97%NewQ4 2025
SYBXSynlogic, Inc.$3.27M0.17%24.98%Not reportedQ3 2017
MRKRMarker Therapeutics, Inc.$2.42M0.12%9.73%Not reportedQ4 2018
OKUROnKure Therapeutics, Inc.$1.39M0.07%143.13%Not reportedQ4 2024
IMAImageneBio, Inc.$345K0.02%0.45%Not reportedQ3 2025
Q3 2025Reported Nov 14, 202529 positions
RYTMRhythm Pharmaceuticals, Inc.$294M16.13%4.36%Not reportedQ4 2017
ACLXArcellx, Inc.$250M13.72%5.27%-18.7%Q1 2022
VRNAVerona Pharma plc$240M13.19%0.33%-0.5%Q2 2017
COURCoursera, Inc.$151M8.27%7.74%Not reportedQ1 2021
TRVITrevi Therapeutics, Inc.$121M6.64%10.31%Not reportedQ2 2019
CELCCelcuity Inc.$106M5.81%4.96%-6.5%Q4 2022
SVRASavara Inc$87.4M4.79%14.16%Not reportedQ1 2021
CRSPCRISPR Therapeutics AG$68.6M3.76%1.13%-33.3%Q4 2016
MBXMBX Biosciences, Inc.$63.3M3.47%8.08%Not reportedQ3 2024
ZBIOZenas BioPharma, Inc.$60.7M3.33%6.48%Not reportedQ3 2024
GLUEMonte Rosa Therapeutics, Inc.$57M3.13%12.45%Not reportedQ2 2021
KRROKorro Bio, Inc.$52.2M2.87%11.61%Not reportedQ4 2023
ORICOric Pharmaceuticals, Inc.$49.4M2.71%4.23%Not reportedQ2 2024
GOSSGossamer Bio, Inc.$47.6M2.61%7.82%Not reportedQ3 2022
AUPHAurinia Pharmaceuticals Inc.$43.9M2.41%3.01%Not reportedQ3 2014
PHATPhathom Pharmaceuticals, Inc.$23.1M1.27%2.76%Not reportedQ2 2023
NEUENeuehealth, Inc.$18.2M1.00%30.22%Not reportedQ2 2023
BDTXBlack Diamond Therapeutics, Inc.$16.9M0.93%7.81%Not reportedQ1 2020
CVRXCVRx, Inc.$16.4M0.90%7.74%Not reportedQ2 2021
CSBRChampions Oncology, Inc.$11.1M0.61%12.43%Not reportedQ3 2015
IVAInventiva S.A.$8.32M0.46%1.53%Not reportedQ3 2020
OMDAOmada Health, Inc.$8.05M0.44%0.63%Not reportedQ2 2025
XFORX4 Pharmaceuticals, Inc$7.64M0.42%8.88%+347.1%Q1 2019
NKTXNkarta, Inc.$7.39M0.41%5.02%Not reportedQ3 2020
SNTISenti Biosciences Holdings, Inc.$5.32M0.29%14.36%Not reportedQ2 2022
SYBXSynlogic, Inc.$4.88M0.27%24.98%Not reportedQ3 2017
MRKRMarker Therapeutics, Inc.$1.45M0.08%9.73%Not reportedQ4 2018
OKUROnKure Therapeutics, Inc.$1.32M0.07%143.13%Not reportedQ4 2024
IMAImageneBio, Inc.$408K0.02%1.24%NewQ3 2025
Premium opens every quarter this fund has filed

Not investment advice. We make every effort to keep the information on SpoorBase accurate, but errors may occur. SpoorBase does not guarantee the accuracy or completeness of any data, and any use of the information is at the user’s sole responsibility. Valuation multiples are calculated by SpoorBase and may contain errors. See Disclosures. © 2026 SpoorBase. All rights reserved.